Nuvo Pharmaceuticals (OTCMKTS:MRVFF – Get Free Report) and Gemini Therapeutics (NASDAQ:GMTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.
Risk & Volatility
Nuvo Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.
Earnings & Valuation
This table compares Nuvo Pharmaceuticals and Gemini Therapeutics’ revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Nuvo Pharmaceuticals | $54.98 million | 0.20 | -$25.70 million | ($0.12) | -8.16 |
Gemini Therapeutics | N/A | N/A | -$71.87 million | ($1.00) | -45.07 |
Institutional and Insider Ownership
75.4% of Gemini Therapeutics shares are held by institutional investors. 7.0% of Nuvo Pharmaceuticals shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings for Nuvo Pharmaceuticals and Gemini Therapeutics, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Nuvo Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
Gemini Therapeutics | 0 | 0 | 0 | 0 | N/A |
Profitability
This table compares Nuvo Pharmaceuticals and Gemini Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Nuvo Pharmaceuticals | 20.88% | -1,996.22% | 14.25% |
Gemini Therapeutics | N/A | -38.78% | -35.88% |
Summary
Nuvo Pharmaceuticals beats Gemini Therapeutics on 7 of the 10 factors compared between the two stocks.
About Nuvo Pharmaceuticals
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.
About Gemini Therapeutics
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Nuvo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.